FLT3-ITD in relapsed/refractory AML: gilteritinib monotherapy superior to salvage chemo (...
Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.
| ID | BMA-FLT3-ITD-AML-RR |
|---|---|
| Tipo | Relevancia terapéutica |
| Situación | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Enfermedades | DIS-AML |
| Fuentes | SRC-ADMIRAL-PERL-2019 SRC-CIVIC SRC-ELN-AML-2022 SRC-NCCN-AML-2025 |
Hechos relativos a la posibilidad de adoptar medidas
| Biomarcador | BIO-FLT3-ITD |
|---|---|
| Variante | internal tandem duplication (relapsed/refractory AML) |
| Enfermedad | DIS-AML |
| El nivel de ESCAT | IA |
| Combinaciones recomendadas | gilteritinib monotherapy (2L bridge to allo-SCT), gilteritinib + venetoclax + azacitidine (off-label intensification, trial) |
| Resumen de las pruebas | FLT3-ITD in relapsed/refractory AML: gilteritinib monotherapy superior to salvage chemo (ADMIRAL, Perl NEJM 2019 — OS 9.3 vs 5.6 mo, HR 0.64). Gilteritinib is preferred 2L for FLT3-mutant R/R AML and is a bridge to allo-SCT. Quizartinib also active R/R (QuANTUM-R) but FDA label is 1L only (R/R label withdrawn). |
Notas
ESCAT IA. OncoKB Level 1. Resistance: F691L gatekeeper, D835 TKD emerge under gilteritinib pressure — see BMA-FLT3-D835-AML-RR and BMA-FLT3-F691L-AML for next-step considerations. Distinguish from BMA-FLT3-ITD-AML which covers 1L.
Utilizado por
No se encuentran referencias inversas en el corpus YAML.